Selected research
Industry Research
Muromonab-CD3 Industry Research Report 2026
Market perspective
The global Muromonab-CD3 market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Muromonab-CD3 is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Muromonab-CD3 is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Muromonab-CD3 is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Muromonab-CD3 include Janssen Pharmaceutica, Wuhan Costan Biotechnology Co., Ltd., Shanghai Hanxiang Biotechnology Co., Ltd., Shaanxi Didu Pharmaceutical Chemical Co., Ltd., Pujian Bio (Wuhan) Technology Co., Ltd., Hubei Shishun Biotechnology Co., Ltd. and Beijing Huamei Huli Biochemical Co., Ltd., among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Muromonab-CD3 market in terms of revenue (US$ million) and, where applicable, sales volume (k units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Muromonab-CD3 Market by Company
Janssen Pharmaceutica
Wuhan Costan Biotechnology Co., Ltd.
Shanghai Hanxiang Biotechnology Co., Ltd.
Shaanxi Didu Pharmaceutical Chemical Co., Ltd.
Pujian Bio (Wuhan) Technology Co., Ltd.
Hubei Shishun Biotechnology Co., Ltd.
Beijing Huamei Huli Biochemical Co., Ltd.
Muromonab-CD3 Segment by Type
99% Purity
Purity>95%
Muromonab-CD3 Segment by Application
Ulcerative Colitis
Crohn's Disease
Anti-acute Rejection
Acute Lymphoblastic Leukemia Treatment
Type-1 Diabetes
Muromonab-CD3 Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Muromonab-CD3 market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Muromonab-CD3 and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Muromonab-CD3.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Muromonab-CD3 manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Muromonab-CD3 by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Muromonab-CD3 in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- 99% Purity
- Purity>95%
Applications
- Ulcerative Colitis
- Crohn's Disease
- Anti-acute Rejection
- Acute Lymphoblastic Leukemia Treatment
- Type-1 Diabetes
Companies covered
- Janssen Pharmaceutica
- Wuhan Costan Biotechnology Co., Ltd.
- Shanghai Hanxiang Biotechnology Co., Ltd.
- Shaanxi Didu Pharmaceutical Chemical Co., Ltd.
- Pujian Bio (Wuhan) Technology Co., Ltd.
- Hubei Shishun Biotechnology Co., Ltd.
- Beijing Huamei Huli Biochemical Co., Ltd.
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Muromonab-CD3 Market Size (2021-2032)
- 2.2.2 Global Muromonab-CD3 Sales (2021-2032)
- 2.2.3 Global Muromonab-CD3 Market Average Price (2021-2032)
- 2.3 Muromonab-CD3 by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 99% Purity
- 2.3.3 Purity>95%
- 2.4 Muromonab-CD3 by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Ulcerative Colitis
- 2.4.3 Crohn's Disease
- 2.4.4 Anti-acute Rejection
- 2.4.5 Acute Lymphoblastic Leukemia Treatment
- 2.4.6 Type-1 Diabetes
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Muromonab-CD3 Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Muromonab-CD3 Sales (k units) of Manufacturers (2021-2026)
- 3.3 Global Muromonab-CD3 Revenue of Manufacturers (2021-2026)
- 3.4 Global Muromonab-CD3 Average Price by Manufacturers (2021-2026)
- 3.5 Global Muromonab-CD3 Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Muromonab-CD3, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Muromonab-CD3, Product Type & Application
- 3.8 Global Manufacturers of Muromonab-CD3, Established Date
- 3.9 Global Muromonab-CD3 Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Janssen Pharmaceutica
- 4.1.1 Janssen Pharmaceutica Company Information
- 4.1.2 Janssen Pharmaceutica Business Overview
- 4.1.3 Janssen Pharmaceutica Muromonab-CD3 Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Janssen Pharmaceutica Muromonab-CD3 Product Portfolio
- 4.1.5 Janssen Pharmaceutica Recent Developments
- 4.2 Wuhan Costan Biotechnology Co., Ltd.
- 4.2.1 Wuhan Costan Biotechnology Co., Ltd. Company Information
- 4.2.2 Wuhan Costan Biotechnology Co., Ltd. Business Overview
- 4.2.3 Wuhan Costan Biotechnology Co., Ltd. Muromonab-CD3 Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Wuhan Costan Biotechnology Co., Ltd. Muromonab-CD3 Product Portfolio
- 4.2.5 Wuhan Costan Biotechnology Co., Ltd. Recent Developments
- 4.3 Shanghai Hanxiang Biotechnology Co., Ltd.
- 4.3.1 Shanghai Hanxiang Biotechnology Co., Ltd. Company Information
- 4.3.2 Shanghai Hanxiang Biotechnology Co., Ltd. Business Overview
- 4.3.3 Shanghai Hanxiang Biotechnology Co., Ltd. Muromonab-CD3 Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Shanghai Hanxiang Biotechnology Co., Ltd. Muromonab-CD3 Product Portfolio
- 4.3.5 Shanghai Hanxiang Biotechnology Co., Ltd. Recent Developments
- 4.4 Shaanxi Didu Pharmaceutical Chemical Co., Ltd.
- 4.4.1 Shaanxi Didu Pharmaceutical Chemical Co., Ltd. Company Information
- 4.4.2 Shaanxi Didu Pharmaceutical Chemical Co., Ltd. Business Overview
- 4.4.3 Shaanxi Didu Pharmaceutical Chemical Co., Ltd. Muromonab-CD3 Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Shaanxi Didu Pharmaceutical Chemical Co., Ltd. Muromonab-CD3 Product Portfolio
- 4.4.5 Shaanxi Didu Pharmaceutical Chemical Co., Ltd. Recent Developments
- 4.5 Pujian Bio (Wuhan) Technology Co., Ltd.
- 4.5.1 Pujian Bio (Wuhan) Technology Co., Ltd. Company Information
- 4.5.2 Pujian Bio (Wuhan) Technology Co., Ltd. Business Overview
- 4.5.3 Pujian Bio (Wuhan) Technology Co., Ltd. Muromonab-CD3 Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Pujian Bio (Wuhan) Technology Co., Ltd. Muromonab-CD3 Product Portfolio
- 4.5.5 Pujian Bio (Wuhan) Technology Co., Ltd. Recent Developments
- 4.6 Hubei Shishun Biotechnology Co., Ltd.
- 4.6.1 Hubei Shishun Biotechnology Co., Ltd. Company Information
- 4.6.2 Hubei Shishun Biotechnology Co., Ltd. Business Overview
- 4.6.3 Hubei Shishun Biotechnology Co., Ltd. Muromonab-CD3 Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Hubei Shishun Biotechnology Co., Ltd. Muromonab-CD3 Product Portfolio
- 4.6.5 Hubei Shishun Biotechnology Co., Ltd. Recent Developments
- 4.7 Beijing Huamei Huli Biochemical Co., Ltd.
- 4.7.1 Beijing Huamei Huli Biochemical Co., Ltd. Company Information
- 4.7.2 Beijing Huamei Huli Biochemical Co., Ltd. Business Overview
- 4.7.3 Beijing Huamei Huli Biochemical Co., Ltd. Muromonab-CD3 Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Beijing Huamei Huli Biochemical Co., Ltd. Muromonab-CD3 Product Portfolio
- 4.7.5 Beijing Huamei Huli Biochemical Co., Ltd. Recent Developments
5 Global Muromonab-CD3 Market Scenario by Region
- 5.1 Global Muromonab-CD3 Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Muromonab-CD3 Sales by Region: 2021-2032
- 5.2.1 Global Muromonab-CD3 Sales by Region: 2021-2026
- 5.2.2 Global Muromonab-CD3 Sales by Region: 2027-2032
- 5.3 Global Muromonab-CD3 Revenue by Region: 2021-2032
- 5.3.1 Global Muromonab-CD3 Revenue by Region: 2021-2026
- 5.3.2 Global Muromonab-CD3 Revenue by Region: 2027-2032
- 5.4 North America Muromonab-CD3 Market Facts & Figures by Country
- 5.4.1 North America Muromonab-CD3 Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Muromonab-CD3 Sales by Country (2021-2032)
- 5.4.3 North America Muromonab-CD3 Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Muromonab-CD3 Market Facts & Figures by Country
- 5.5.1 Europe Muromonab-CD3 Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Muromonab-CD3 Sales by Country (2021-2032)
- 5.5.3 Europe Muromonab-CD3 Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Muromonab-CD3 Market Facts & Figures by Country
- 5.6.1 Asia Pacific Muromonab-CD3 Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Muromonab-CD3 Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Muromonab-CD3 Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Muromonab-CD3 Market Facts & Figures by Country
- 5.7.1 South America Muromonab-CD3 Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Muromonab-CD3 Sales by Country (2021-2032)
- 5.7.3 South America Muromonab-CD3 Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Muromonab-CD3 Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Muromonab-CD3 Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Muromonab-CD3 Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Muromonab-CD3 Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Muromonab-CD3 Sales by Type (2021-2032)
- 6.1.1 Global Muromonab-CD3 Sales by Type (2021-2032) & (k units)
- 6.1.2 Global Muromonab-CD3 Sales Market Share by Type (2021-2032)
- 6.2 Global Muromonab-CD3 Revenue by Type (2021-2032)
- 6.2.1 Global Muromonab-CD3 Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Muromonab-CD3 Revenue Market Share by Type (2021-2032)
- 6.3 Global Muromonab-CD3 Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Muromonab-CD3 Sales by Application (2021-2032)
- 7.1.1 Global Muromonab-CD3 Sales by Application (2021-2032) & (k units)
- 7.1.2 Global Muromonab-CD3 Sales Market Share by Application (2021-2032)
- 7.2 Global Muromonab-CD3 Revenue by Application (2021-2032)
- 7.2.1 Global Muromonab-CD3 Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Muromonab-CD3 Revenue Market Share by Application (2021-2032)
- 7.3 Global Muromonab-CD3 Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Muromonab-CD3 Value Chain Analysis
- 8.1.1 Muromonab-CD3 Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Muromonab-CD3 Production Mode & Process
- 8.2 Muromonab-CD3 Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Muromonab-CD3 Distributors
- 8.2.3 Muromonab-CD3 Customers
9 Global Muromonab-CD3 Analyzing Market Dynamics
- 9.1 Muromonab-CD3 Industry Trends
- 9.2 Muromonab-CD3 Industry Drivers
- 9.3 Muromonab-CD3 Industry Opportunities and Challenges
- 9.4 Muromonab-CD3 Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst